Immuneering Corporation (IMRX) Stock Price, Quote, News & Analysis

IMRX Immuneering Corporation
Stock Price & Overview

$1.39-0.03 (-2.11%)4:00 PM 05/24/24
NASDAQ | $USD | Post-Market: $1.39 7:23 PM

Charts

52 Week Range
1.36
11.92
Day Range
1.39
1.39
EPS (FWD)
-2.00
PE
-
Div Rate
-
Yield
-
Market Cap
$41.22M
Volume
183,493
Prev. Close
$1.42
Expand For Key Data »

Quant Ranking

IMRX Analysis

IMRX News

See All News »

Latest Headlines

Ratings Summary

People Also Follow

Compare

Similar to IMRX

SymbolLast PriceChange
EVGN
0
0.00%
Evogene Ltd.
MTNB
0
0.00%
Matinas BioPharma Holdings, Inc.
HCWB
0
0.00%
HCW Biologics Inc.
ACXP
0
0.00%
Acurx Pharmaceuticals, Inc.
MSCLF
0
0.00%
SATELLOS BIOSCIENCE INC.
Compare

ETFs Holding IMRX

IMRX Company Profile

Immuneering Corporation logo
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Employees
65
Founded
2008
Address
  • 245 Main Street
  • Second Floor
  • Cambridge, MA, 02142
  • United States
Phone Number
617 500 8080
Website
immuneering.com
Hide

IMRX Revenue

More On Revenue »

IMRX Earnings Per Share

More On Earnings »

Earnings Estimates

FY
EPS
YoY
PE
Sales
YoY
2024
-2.00
-6.47%
-0.69
$0.00
-
2025
-1.59
+20.37%
-0.87
$0.00
-
2026
-1.94
-21.71%
-0.72
$0.00
-
More On Earnings Estimates »

Earnings Revisions

Rating:
FY1 Up Revisions
3
FY1 Down Revisions
3
50% Down50% Up
More On Earnings Revisions »

Valuation

Rating:
P/E Non-GAAP (FWD)
-
P/E GAAP (TTM)
NM
Price/Book (TTM)
0.52
EV/Sales (TTM)
NM
EV/EBITDA (TTM)
NM
More On Valuation »

Growth

Rating:
Revenue (YoY)
-99.91%
Revenue 3 Year (CAGR)
-45.14%
EPS Diluted (YoY)
-
EPS Diluted 3 Year (CAGR)
-
Levered FCF (YoY)
-
More On Growth »

Profitability

Rating:
Gross Profit Margin
100.00%
EBIT Margin
-
Net Income Margin
-
Return on Equity
-61.38%
Return on Assets
-61.57%
More On Profitability »

Momentum

Rating:
Ticker
3M
6M
9M
1Y
IMRX
-78.48%
-81.95%
-85.63%
-78.62%
SP500
+4.24%
+16.35%
+21.21%
+28.90%

52 Week Range

1.36
Last price: 1.39
11.92
More On Momentum »

Capital Structure

Market Cap
$41.22M
Total Debt
$4.38M
Cash
$71.28M
Other
-
Enterprise Value
-$25.68M

Trading Data

Volume
183,493
Average Volume (3 months)
727,208
Previous Close
1.42
Open
1.44
Shares Outstanding (Ticker)
29.65M

Dividends

IMRX does not currently pay a dividend.

IMRX Ownership

Type
Common Stock Held
% of Shares Outstanding
Market Value
Composition
Institutions
6.73M
22.68%
9.35M
Corporations (Private)
4,897
0.02%
6,807
Individuals / Insiders
8.66M
29.19%
12.03M
Hedge Fund Managers
3.58M
12.08%
4.98M
Public and Other
10.68M
36.03%
14.85M
Total
29.65M
100.00%
41.22M

IMRX Peers

Title
EVGNMTNBHCWBACXP
Company name
Evogene Ltd.
Matinas BioPharma Holdings, Inc.
HCW Biologics Inc.
Acurx Pharmaceuticals, Inc.
Industry
BiotechnologyBiotechnologyBiotechnologyBiotechnology
Market Cap
40.91M
41.64M
41.98M
39.72M
Employees
142
32
45
4

Go Premium to see ratings on IMRX peers.

More On Peers »

Risk

24M Beta
0.28
Altman Z Score
11.68

Technicals

Title
10D SMA
50D SMA
200D SMA
Simple Moving Average
1.51
1.91
5.71
Last Price vs SMA
-8.19%
-27.29%
-75.65%
More On Moving Averages »

IMRX Transcripts

Investor Presentations

IMRX SEC Filings

See All SEC Filings »

Press Releases

See All Press Releases »

IMRX Income Statement

Revenue (TTM)
455.00
Revenue Per Share
0.00
Gross Profit (TTM)
455.00
EBITDA (TTM)
-58.69M
Net Income (TTM)
-54.18M
EPS Diluted (TTM)
-$1.86
Full Income Statement »

IMRX Balance Sheet

Total Cash (MRQ)
71.28M
Total Cash Per Share
2.24
Total Debt (MRQ)
4.38M
Total Debt to Equity (MRQ)
5.57%
Current Ratio (MRQ)
14.38
Quick Ratio (MRQ)
13.77
Full Balance Sheet »

IMRX Cash Flow Statement

Cash from Operations (TTM)
-50.04M
Cash from Investing (TTM)
9.72M
Levered Free Cash Flow (TTM)
-31.72M
Unlevered Free Cash Flow (TTM)
-31.72M
Free Cash Flow / Share (TTM)
-$1.73
Full Cash Flow Statement »

IMRX Long Term Solvency

Total Debt / Equity (MRQ)
5.57
Total Debt / Capital (MRQ)
5.27
LT Debt / Equity (MRQ)
5.19
LT Debt / Total Capital (MRQ)
4.91
Total Liabilities / Total Assets (MRQ)
10.52

Discover More

You may be interested in:

Immuneering Corporation (IMRX) Frequently Asked Questions

  • 8 Wall Street analysts have issued ratings. Currently, 6 analysts rated IMRX as Bullish, 0 rated it Bearish, and 2 rated it Neutral for a Wall Street consensus of buy. View IMRX’s ratings here. 1 Seeking Alpha authors also rated the stock, and their ratings often outperform those of Wall Street analysts. Here are their ratings on IMRX

  • Immuneering Corporation is currently listed on NASDAQ under IMRX. One share of IMRX stock can currently be purchased for approximately $1.39.

  • Immuneering Corporation is listed on the NASDAQ as (NASDAQ:IMRX).

  • Immuneering Corporation's stock symbol is IMRX and currently trades under NASDAQ. It’s current price per share is approximately $1.39.

  • 8 Wall Street analysts have issued ratings. Currently, 6 analysts rated IMRX as Bullish, 0 rated it Bearish, and 2 rated it Neutral. This suggests a possible increase. View IMRX’s analyst predictions. 1 Seeking Alpha authors also rated the stock, and their ratings often outperform those of Wall Street analysts. Here are their ratings on IMRX

  • Immuneering Corporation has not had any stock splits.

  • Immuneering Corporation’s EPS last quarter was $-0.49 and revenues were $455. Immuneering Corporation’s latest EPS estimate is $-0.54. Read more about Immuneering Corporation’s earnings here.

  • IMRX’s market capitalization is currently $41.22M and its latest reported revenue was $455. Read more about Immuneering Corporation’s finances here.

  • Immuneering Corporation’s revenue estimate for 2024 is $0. The latest low revenue estimate is $0 and the high revenue estimate is $0. Learn more about Immuneering Corporation’s revenue estimate.

  • People who follow Immuneering Corporation (IMRX) also follow IKNA, RPHM, INZY, HCWB. Read more about IMRX’s peers.

People Also Follow

Compare

Similar to IMRX

SymbolLast PriceChange
EVGN
0
0.00%
Evogene Ltd.
MTNB
0
0.00%
Matinas BioPharma Holdings, Inc.
HCWB
0
0.00%
HCW Biologics Inc.
ACXP
0
0.00%
Acurx Pharmaceuticals, Inc.
MSCLF
0
0.00%
SATELLOS BIOSCIENCE INC.
Compare

ETFs Holding IMRX